Skip to main content
letter
. 2021 Jan;18(1):174–177. doi: 10.1513/AnnalsATS.202006-702RL

Figure 1.

Figure 1.

Trends in serum VEGF-C (vascular endothelial growth factor C) values in the MILES (Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus) trial. (A) In the treatment group, serum VEGF-C concentrations decreased in the first 12 mo when patients were receiving sirolimus and returned toward the baseline values in the observation period off sirolimus. (B) In the placebo group, serum VEGF-C concentrations remained stable throughout the 2-yr study duration. *P < 0.05.